1 Department of Pharmacy, University clinical hospital“Lozano Blesa”, Zaragoza, Spain.
2 Unit for the Rational Use of Medicines, Aragon Health Service, Zaragoza, Spain.
International Journal of Science and Research Archive, 2025, 16(03), 1338-1341
Article DOI: 10.30574/ijsra.2025.16.3.2739
Received on 23 August 2025; revised on 28 September 2025; accepted on 30 September 2025
Objective: To analyze the association between chronic lithium treatment and hyperparathyroidism, exploring pathophysiological mechanisms, clinical manifestations, diagnostic approaches, and management strategies.
Methods: A review of clinical cases and literature evidence is presented, integrating findings from real-world psychiatric populations.
Results: Lithium use was associated with elevated serum calcium and parathyroid hormone (PTH) levels, increasing the risk of nephrolithiasis, osteoporosis, and cardiovascular complications.
Discussion: Hyperparathyroidism secondary to lithium therapy represents a significant but often overlooked adverse effect. Its detection requires systematic biochemical monitoring and clinical awareness. Conclusion: Regular calcium and PTH assessments are recommended in patients receiving lithium, with individualized management strategies including dose adjustment, medical therapy, or parathyroidectomy in selected cases.
Lithium; Hyperparathyroidism; Bipolar disorder; Calcium metabolism; Endocrine side effects
Preview Article PDF
Roberto Lozano and Carina Bona. Lithium treatment and hyperparathyroidism: Clinical implications and management. International Journal of Science and Research Archive, 2025, 16(03), 1338-1341. Article DOI: https://doi.org/10.30574/ijsra.2025.16.3.2739.
Copyright © 2025 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
